🔎 Trials Near Me

Home › Alcohol Use Disorder (AUD) › NCT06305624

Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

Recruiting

Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease (IMPACT-ALD): Aim 1

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria (Aim 1):

* Diagnosis of ALD (any stage)
* Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries caused by long-term alcohol abuse. For this study, participants will have a diagnosis of ALD or evidence of the combination of liver disease and alcohol misuse in electronic health record.
* Alcohol use within the last 6 months
* Receiving care at UW or Henry Ford Health + MSU

  * Either the general hepatology clinic or the multidisciplinary ALD clinic
* Able to read and write proficiently in English
* Willing and able to use a smartphone app

Exclusion Criteria:

* Actively listed for liver transplant or history of liver transplant before being enrolled in the study. Participants added to a liver transplant list after being enrolled in the study will be allowed to continue their participation
* In hospice care
* Has severe cognitive impairment (as described in electronic health record including dementia, delirium, and/or unable to maintain cognitive alertness during screening--as determined by study staff.)

About the study

This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months.

What is being tested

Sponsor: University of Wisconsin, Madison · Participants: 298 · Started: Jun 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06305624

Locations in the U.S.

MichiganHenry Ford + Michigan State University Health Center, Lansing
WisconsinUW General Hepatology Clinic, Madison
UW Multidisciplinary ALD Clinic, Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.